BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Pfizer

The FDA has raised the bar for vaccine makers.

Why COVID Vaccines for Younger Kids Won't Win Authorization as Soon as Expected

Dynavax Technologies

Novavax

Each vaccine stock had its own separate catalyst.

Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week

Barrick Gold

Workhorse Group

Earnings reports released Thursday morning showed about a two-to-one edge for stocks beating estimates.

Earnings Previews: Barrick Gold, BioNTech, Workhorse and 2 Cathie Wood Picks

It might seem to be the case, at least at first glance.

Is BioNTech Contradicting Pfizer About the Need for Booster Doses?

Moderna, Inc. (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) shares have been on tear ever since these companies embarked on their respective COVID-19 vaccine programs. Shares of both companies are trading just shy of their all-time highs.

Moderna Vs. BioNTech: How Do These High-Flying COVID-19 Vaccine Stocks Compare?

Moderna and BioNTech have climbed in recent weeks as the resurgent Delta variant has captured headlines.

Moderna and BioNTech stocks are surging amid reports of FDA vaccine-approval progress

Gilead Sciences

MAINZ, Germany & SANTA MONICA, Calif.--(BUSINESS WIRE)--BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility's assets and leases in Gaithersburg, MD, from Kite. The transaction was announced on July 19, 2021. The acquisition strengthens BioNTech's cell therapy pipeline by accelerating the individualized solid

BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

The Food and Drug Administration says it's engaged in an “all-hands-on-deck approach” to granting full approval to Pfizer's coronavirus vaccine.

FDA Reportedly Hopes To Fully Approve Pfizer's Covid Vaccine By Labor Day

The U.S. Food and Drug Administration is aiming to grant full approval of the Pfizer-BioNTech coronavirus vaccine by Labor Day or sooner, according to a new report.

FDA aims for full approval of Pfizer COVID-19 vaccine by Labor Day: report

The pharmaceutical company filed its application with the FDA on May 7, and the FDA is expected to finish it's approval process by Labor Day weekend.

FDA expected to approve Pfizer-BioNTech's COVID-19 vaccine by early September: NYT

On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.

BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?

Mainz, Germany, August 2, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter on Monday, August 9th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2021.

BioNTech to Report Second Quarter Financial Results and Operational Update on August 9, 2021

Pfizer, Inc. (NYSE: PFE) and Moderna, Inc. (NASDAQ: MRNA), which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more. What Happened: Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.

Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report

There is market concern about the emergence of the Delta variant of SARS-CoV-2. Delta is dangerous, but it looks containable with existing vaccines; the danger comes from new variants that are appearing.

Delta Variant And The Markets

Innovative Industrial Properties

NextEra Energy

It doesn't take much money -- or a lot of time, really -- to make $1 million.

Investing in These Stocks Now Could Make You a Millionaire Retiree

Amazon

Alphabet

Microsoft

The market has been on edge over the new delta variant. Here are five stocks to help blunt a worst-case scenario.

Worried About the Delta Variant? 5 Stocks to Insulate You From a COVID Market Crash

The two companies behind the gene-based COVID vaccines are a lot different than you might think.

Better Biotech Stock: Moderna vs. BioNTech

What Would Full FDA Approval of Pfizer's COVID Vaccine Mean for the Stock?

There are several pluses for BioNTech in the deal.

Why Investors Should Like BioNTech's Latest Deal With Gilead

There was more good news for the company's COVID-19 vaccine.

Why BioNTech Stock Jumped This Week

Millions of Americans still really, really don't want to get vaccinated.

Why Moderna and BioNTech Slipped Today

Israeli health officials said they've seen protection against severe illness from Pfizer's vaccine decrease from 97% to 81% over time.

Israel will roll out a booster dose of the Pfizer-BioNTech COVID-19 vaccine to older people, citing a drop in protection against severe disease driven by the Delta variant

Bioline RX

Canadian Solar

Danaos

Global Ship Lease

Jumia

Goldman Sachs JUST US Large Cap Equity ETF

Lithium Americas Corp

VanEck Rare Earth/Strategic Metals ETF

SSR Mining

Universal Insurance Hlds

Viatris

Zogenix

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

2021 Top Idea Contest - New Ideas

A confluence of COVID-19 news conspired to drive shares of the biotechnology company higher.

Why BioNTech Stock Shot Higher on Wednesday

Pfizer's vaccine initially protects people 100% of the time against hospitalization, but that falls to low 90% and mid-to-high 80% after six months, Bourla said

News for BioNTech SE Stock (BNTX)